Operating Segments

6 Months Ended

12 Months Ended

Jun. 30, 2015

Dec. 31, 2014

Operating Segments [Abstract]

Operating Segments

Note 8. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

  

	Three Months Ended  June 30,
	2015				2014
Contract/Grant Revenue
Vaccines/BioDefense	$	1,099,827			$	1,321,385
BioTherapeutics		—				96,863
Total	$	1,099,827			$	1,418,248
Income (Loss) from Operations
Vaccines/BioDefense	$	302,531			$	264,810
BioTherapeutics		(1,383,167	)			(650,477	)
Corporate		(954,115	)			(1,310,164	)
Total	$	(2,034,751	)	$	(1,695,831	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,941			$	9,809
BioTherapeutics		49,866				49,072
Corporate		1,924				1,526
Total	$	61,731			$	60,407
Other Income / (Expense), Net
Corporate	$	(1,942,943	)		$	747,314
Share-Based Compensation
Vaccines/BioDefense	$	19,344			$	10,450
BioTherapeutics		30,179				33,135
Corporate		87,640				77,672
Total	$	137,163			$	121,257

	Six Months Ended  June 30,
	2015			2014
Contract/Grant Revenue
Vaccines/BioDefense	$	1,902,141		$	2,198,430
BioTherapeutics		13,972			130,415
Total	$	1,916,113		$	2,328,845
Income (Loss) from Operations
Vaccines/BioDefense	$	387,212		$	404,214
BioTherapeutics		(2,148,043	)		(1,686,068	)
Corporate		(1,832,187	)		(2,003,886	)
Total	$	(3,593,018	)	$	(3,285,740	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	19,727		$	19,744
BioTherapeutics		98,240			99,011
Corporate		3,690			3,739
Total	$	121,657		$	122,494
Other Income / (Expense), Net
Corporate	$	(4,953,998	)	$	(994,485	)
Share-Based Compensation
Vaccines/BioDefense	$	43,936		$	20,900
BioTherapeutics		59,435			109,256
Corporate		175,817			167,763
Total	$	279,188		$	297,919

	As of  June 30,  2015		As of  December 31,  2014
Identifiable Assets
Vaccines/BioDefense	$945,991		$1,025,220
BioTherapeutics		113,916		204,308
Corporate		4,306,282		5,724,720
Total	$	5,366,189	$	6,954,248

Note 10. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Years Ended December 31,
	2014			2013
Revenues
Vaccines/BioDefense	$	6,756,388		$	3,003,822
BioTherapeutics		286,628			220,330
Total	$	7,043,016		$	3,224,152
Income (loss) from Operations
Vaccines/BioDefense	$	807,164		$	(1,666,130	)
BioTherapeutics		(7,674,381	)		(3,069,998	)
Corporate		(3,894,132	)		(2,420,414	)
Total	$	(10,761,349	)	$	(7,156,542	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	39,625		$	37,981
BioTherapeutics		199,196			190,033
Corporate		6,966			2,057
Total	$	245,787		$	230,071
Interest Income
Corporate	$	1,310		$	1,960
Stock-Based Compensation
Vaccines/BioDefense	$	114,920		$	80,432
BioTherapeutics		193,926			250,431
Corporate		411,304			472,197
Total	$	720,150		$	803,060

	As of December 31,
	2014		2013
Identifiable Assets
Vaccines/BioDefense	$	1,025,220	$	1,870,414
BioTherapeutics		204,308		386,721
Corporate		5,724,720		6,008,320
Total	$	6,954,248	$	8,265,455